Home/MapLight Therapeutics/Christopher G. Verni, Ph.D.
CG

Christopher G. Verni, Ph.D.

Chief Executive Officer

MapLight Therapeutics

MapLight Therapeutics Pipeline

DrugIndicationPhase
ML-007Social impairment in Autism Spectrum DisorderPhase 2
ML-104Treatment-resistant DepressionPreclinical
ML-225Cognitive impairment in Alzheimer's DiseasePreclinical
Undisclosed ProgramAnxiety DisordersDiscovery